Pharma Institute India
- All
- News
- Videos
-
Centre Approves Rs 700 Crore To Set Up Institutes Of Pharma, Medical Technology
- Friday June 28, 2024
- India News | Indo-Asian News Service
The Central government has earmarked Rs 700 crore to set up centres of excellence at the National Institutes of Pharmaceutical, Education & Research (NIPER) over the next five years to boost pharma and medical technology in the country.
- www.ndtv.com
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
- Wednesday May 8, 2024
- India News | Reported by Vishnu Som
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
- www.ndtv.com
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
- Wednesday May 8, 2024
- India News | NDTV News Desk
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
- www.ndtv.com
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
- Monday May 6, 2024
- India News | Reported by Ashish Bhargava
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
- www.ndtv.com
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
- Friday May 3, 2024
- India News | NDTV News Desk
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
- www.ndtv.com
-
IIT Kanpur Professor Wins Sun Pharma Science Foundation Research Award
- Monday January 24, 2022
- Education | Edited by Bishal Kalita
Dr Ateeq is a recipient of the Shanti Swarup Bhatnagar Prize in Medical Sciences (2020). She is also an Elected Fellow of the National Academy of Sciences, India (NASI) and the Indian Academy of Sciences, Bangalore (IASc).
- www.ndtv.com/education
-
Hyderabad Pharma Firm Signs Agreement To Make Covid Drug 2-DG
- Wednesday June 9, 2021
- India News | Press Trust of India
Hyderabad-based Lee Pharma has entered into an agreement with the Indian Institute of Chemical Technology (IICT), a constituent laboratory of CSIR, to manufacture and commercialise 2-DG used to treat Covid patients, a statement said.
- www.ndtv.com
-
From May 1, Pay More For Second Jab Of Covishield
- Wednesday April 21, 2021
- Business | Reported by Animesh Singh
COVID-19 vaccine: From May 1, 2021, a jab of Serum Institute of India's Covishield vaccine will cost Rs 600 in private hospitals.
- www.ndtv.com/business
-
AstraZeneca, Novavax Ready To Scale Up COVID-19 Vaccine Production In Tie-Up With Serum Institute
- Thursday February 25, 2021
- India News | Press Trust of India
British-Swedish pharma giant AstraZeneca and US pharmaceutical major Novavax have told lawmakers that they are ready to scale up their production of COVID-19 vaccines in partnership with the Serum Institute of India.
- www.ndtv.com
-
"Please Be Patient": Adar Poonawalla To Nations Waiting For Vaccines
- Sunday February 21, 2021
- India News | Reported by Vishnu Som, Edited by Swati Bhasin
World's biggest vaccine maker Serum Institute of India's Adar Poonawalla this morning urged the nations to "be patient" amid the wait for Covishield, the coronavirus vaccine that the SII has developed in partnership with the Oxford University and British-Swedish pharma firm AstraZeneca.
- www.ndtv.com
-
Russian Covid Vaccine Sputnik Could Be Available In India By April: 10 Points
- Thursday February 4, 2021
- India News | Reported by Vishnu Som
Russian-made Coronavirus vaccine Sputnik -- peer-reviewed by the Lancet Medical Journal -- is undergoing trials in India and could be available for use soon. "I believe the vaccine should be available in India from March- April," Deepak Sapra, the chief of API and pharma services at Dr Reddy's Laboratories, which is manufacturing the vaccine, told...
- www.ndtv.com
-
"Hope To Launch Covovax By June 2021": Serum Institute's Adar Poonawalla
- Saturday January 30, 2021
- India News | Edited by Swati Bhasin
Serum Institute of India, the world's biggest vaccine maker, is hopeful of launching Covovax - developed in partnership with American vaccine developer Novavax - by June, its CEO Adar Poonawalla said today. The US-based pharma firm's Covid jab was found to be 89.3 per cent effective in a UK trial.
- www.ndtv.com
-
Will Receive Two Million AstraZeneca Doses By Friday From India: Brazil
- Friday January 22, 2021
- Business | Edited by Nirmalya Sen
The announcement comes amid delays in receiving the vaccine from India, the latest in a series of miscues surrounding the country's inoculations drive
- www.ndtv.com/business
-
Centre Approves Rs 700 Crore To Set Up Institutes Of Pharma, Medical Technology
- Friday June 28, 2024
- India News | Indo-Asian News Service
The Central government has earmarked Rs 700 crore to set up centres of excellence at the National Institutes of Pharmaceutical, Education & Research (NIPER) over the next five years to boost pharma and medical technology in the country.
- www.ndtv.com
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
- Wednesday May 8, 2024
- India News | Reported by Vishnu Som
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
- www.ndtv.com
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
- Wednesday May 8, 2024
- India News | NDTV News Desk
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
- www.ndtv.com
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
- Monday May 6, 2024
- India News | Reported by Ashish Bhargava
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
- www.ndtv.com
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
- Friday May 3, 2024
- India News | NDTV News Desk
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
- www.ndtv.com
-
IIT Kanpur Professor Wins Sun Pharma Science Foundation Research Award
- Monday January 24, 2022
- Education | Edited by Bishal Kalita
Dr Ateeq is a recipient of the Shanti Swarup Bhatnagar Prize in Medical Sciences (2020). She is also an Elected Fellow of the National Academy of Sciences, India (NASI) and the Indian Academy of Sciences, Bangalore (IASc).
- www.ndtv.com/education
-
Hyderabad Pharma Firm Signs Agreement To Make Covid Drug 2-DG
- Wednesday June 9, 2021
- India News | Press Trust of India
Hyderabad-based Lee Pharma has entered into an agreement with the Indian Institute of Chemical Technology (IICT), a constituent laboratory of CSIR, to manufacture and commercialise 2-DG used to treat Covid patients, a statement said.
- www.ndtv.com
-
From May 1, Pay More For Second Jab Of Covishield
- Wednesday April 21, 2021
- Business | Reported by Animesh Singh
COVID-19 vaccine: From May 1, 2021, a jab of Serum Institute of India's Covishield vaccine will cost Rs 600 in private hospitals.
- www.ndtv.com/business
-
AstraZeneca, Novavax Ready To Scale Up COVID-19 Vaccine Production In Tie-Up With Serum Institute
- Thursday February 25, 2021
- India News | Press Trust of India
British-Swedish pharma giant AstraZeneca and US pharmaceutical major Novavax have told lawmakers that they are ready to scale up their production of COVID-19 vaccines in partnership with the Serum Institute of India.
- www.ndtv.com
-
"Please Be Patient": Adar Poonawalla To Nations Waiting For Vaccines
- Sunday February 21, 2021
- India News | Reported by Vishnu Som, Edited by Swati Bhasin
World's biggest vaccine maker Serum Institute of India's Adar Poonawalla this morning urged the nations to "be patient" amid the wait for Covishield, the coronavirus vaccine that the SII has developed in partnership with the Oxford University and British-Swedish pharma firm AstraZeneca.
- www.ndtv.com
-
Russian Covid Vaccine Sputnik Could Be Available In India By April: 10 Points
- Thursday February 4, 2021
- India News | Reported by Vishnu Som
Russian-made Coronavirus vaccine Sputnik -- peer-reviewed by the Lancet Medical Journal -- is undergoing trials in India and could be available for use soon. "I believe the vaccine should be available in India from March- April," Deepak Sapra, the chief of API and pharma services at Dr Reddy's Laboratories, which is manufacturing the vaccine, told...
- www.ndtv.com
-
"Hope To Launch Covovax By June 2021": Serum Institute's Adar Poonawalla
- Saturday January 30, 2021
- India News | Edited by Swati Bhasin
Serum Institute of India, the world's biggest vaccine maker, is hopeful of launching Covovax - developed in partnership with American vaccine developer Novavax - by June, its CEO Adar Poonawalla said today. The US-based pharma firm's Covid jab was found to be 89.3 per cent effective in a UK trial.
- www.ndtv.com
-
Will Receive Two Million AstraZeneca Doses By Friday From India: Brazil
- Friday January 22, 2021
- Business | Edited by Nirmalya Sen
The announcement comes amid delays in receiving the vaccine from India, the latest in a series of miscues surrounding the country's inoculations drive
- www.ndtv.com/business